Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Orange Book Blog: At the Intersection of Patent Law and FDA Law

Intellectual Property Law

: Orange Book Blog: At the Intersection of Patent Law and FDA Law

IIR "Generic Drugs Summit," Washington, D.C., June 18-20

By Aaron Barkoff

The Institute for International Research will be holding its 9th annual "Generic Drugs Summit," June 18-20 in Washington, D.C.

According to IIR, this is "the leading independent forum addressing business and legal concerns impacting the generics marketplace.  This event attracts 200+ senior-level professionals representing government, regulatory and legal affairs as well as marketing, sales and business development."

The agenda on June 19-20 includes many interesting presentations:

• "Update on Hatch-Waxman Reform," by none other than Rep. Henry A. Waxman
• "Removing Hurdles that Slow Affordable Generics from Coming to Market," by Sen. Debbie A. Stabenow
• "The Future of Biogenerics and Other Measures to Reduce Healthcare Costs," by Rep. Frank Pallone, Jr.
• "Federal Trade Commission Actions Involving Generic Drugs," by Phil Eisenstat, Sr. Attorney, FTC
• "Patent Reform: A Generic Industry Friend or Foe?"
• "The Changing Competitive Landscape of the Generic Drugs Industry"
• "Understanding the 180-Day Forfeiture Provisions of the MMA" (I'll be presenting this topic)
• "Trends in New Pharmaceutical Patent Claim Strategies"

In addition, the Generic Drugs Summit features two pre-conference workshops on June 18: "Strategies for Filing Successful Paragraph IV Certifications" and "Understanding How to Submit Quality ANDAs Based on QbR to Reduce Approval Time."

For more information or to register, please visit the conference website.

Full post as published by Orange Book Blog: At the Intersection of Patent Law and FDA Law on May 16, 2008 (boomark / email).